Shattuck Labs, Inc. Revenue
Shattuck Labs, Inc. (STTK) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.00M, a 66.63% decline year-over-year.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.00M, a 82.52% decline from fiscal 2024.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $5.72M, a 245.26% increase from fiscal 2023.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.66M, a 154.14% increase from fiscal 2022.
- Shattuck Labs, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $652.00K, a 97.83% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $1.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $1.00M derived: sum of 3 quarters · filed 2026-05-07 | $1.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.00M derived: sum of 2 quarters · filed 2026-03-05 | $1.00M derived: sum of 3 quarters · filed 2026-08-11 | $1.00M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-06 | $1.00M derived: sum of 2 quarters · filed 2026-08-11 | $1.00M 10-Q · filed 2025-11-06 | $1.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $3.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $3.00M derived: sum of 3 quarters · filed 2026-05-07 | $4.61M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.00M derived: sum of 2 quarters · filed 2026-03-05 | $4.61M derived: sum of 3 quarters · filed 2026-03-05 | $5.72M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-06 | $4.61M derived: sum of 2 quarters · filed 2025-11-06 | $5.72M 10-Q · filed 2025-11-06 | $6.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.61M 10-Q · filed 2025-08-14 | $2.72M 10-Q · filed 2025-08-14 | $3.44M derived: sum of 3 quarters · filed 2025-08-14 | $4.12M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.11M 10-Q · filed 2025-05-01 | $1.83M derived: sum of 2 quarters · filed 2025-05-01 | $2.52M derived: sum of 3 quarters · filed 2025-05-01 | $2.71M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $714.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.40M derived: sum of 2 quarters · filed 2025-03-27 | $1.60M derived: sum of 3 quarters · filed 2025-03-27 | $1.66M 10-K · filed 2025-03-27 |
| 2023-09-30 | $686.00K 10-Q · filed 2024-11-14 | $886.00K derived: sum of 2 quarters · filed 2024-11-14 | $943.00K 10-Q · filed 2024-11-14 | $1.33M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-01 | $257.00K 10-Q · filed 2024-08-01 | $647.00K derived: sum of 3 quarters · filed 2024-08-01 | $859.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $57.00K 10-Q · filed 2024-05-02 | $447.00K derived: sum of 2 quarters · filed 2024-05-02 | $659.00K derived: sum of 3 quarters · filed 2024-05-02 | $709.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $602.00K derived: sum of 2 quarters · filed 2024-02-29 | $652.00K derived: sum of 3 quarters · filed 2024-02-29 | $652.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $212.00K 10-Q · filed 2023-11-09 | $262.00K derived: sum of 2 quarters · filed 2023-11-09 | $262.00K 10-Q · filed 2023-11-09 | $30.34M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $50.00K 10-Q · filed 2023-08-10 | $50.00K 10-Q · filed 2023-08-10 | $30.13M derived: sum of 3 quarters · filed 2023-08-10 | $32.03M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $30.08M derived: sum of 2 quarters · filed 2023-05-09 | $31.98M derived: sum of 3 quarters · filed 2023-05-09 | $27.75M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $30.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $31.98M derived: sum of 2 quarters · filed 2023-02-23 | $27.75M derived: sum of 3 quarters · filed 2023-02-23 | $30.02M 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.90M 10-Q · filed 2022-11-09 | -$2.33M derived: sum of 2 quarters · filed 2022-11-09 | -$61.00K 10-Q · filed 2022-11-09 | $1.28M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$4.23M 10-Q · filed 2022-08-11 | -$1.96M 10-Q · filed 2022-08-11 | -$619.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.82M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.27M 10-Q · filed 2022-05-12 | $3.61M derived: sum of 2 quarters · filed 2022-05-12 | $6.05M derived: sum of 3 quarters · filed 2022-05-12 | $9.23M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $3.78M derived: sum of 2 quarters · filed 2022-03-15 | $6.96M derived: sum of 3 quarters · filed 2022-03-15 | $9.93M 10-K · filed 2022-03-15 |
| 2020-09-30 | $2.44M 10-Q · filed 2021-11-09 | $5.62M derived: sum of 2 quarters · filed 2021-11-09 | $8.59M 10-Q · filed 2021-11-09 | $11.41M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $3.18M 10-Q · filed 2021-08-12 | $6.16M 10-Q · filed 2021-08-12 | $8.98M derived: sum of 3 quarters · filed 2021-08-12 | $10.76M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $2.98M 10-Q · filed 2021-05-10 | $5.80M derived: sum of 2 quarters · filed 2021-05-10 | $7.58M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $4.61M derived: sum of 2 quarters · filed 2021-03-16 | $9.89M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $1.78M 10-Q · filed 2020-11-13 | $7.07M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |